MEDIMMUNE, WYETH TO LAUNCH RESPIGAM FOR RSV PROPHYLAXIS IN SEPTEMBER WITH PARENT EDUCATION; PHARMACOECONOMIC STUDIES WILL BE PROMOTED TO MCOs
Executive Summary
MedImmune and Wyeth-Lederle will begin the full launch of MedImmune's RespiGam (respiratory syncytial virus I.V. immune globulin) in September, just prior to the start of the 1996 RSV season, the Gaithersburg, Md.-based company reported following approval of the product Jan. 18.